Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Article
Google Scholar
Cunningham D, Allum WH, Stenning SP, Thompson JN, de Velde C, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
Article
CAS
Google Scholar
Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.
Article
CAS
Google Scholar
van Hagen P, Hulshof M, Lanschot J, Steyerberg EW, van Berg Henegouwen MI, Wijnhoven B, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.
Article
Google Scholar
Eto K, Hiki N, Kumagai K, Shoji Y, Tsuda Y, Kano Y, et al. Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications. Gastric Cancer. 2018;21(4):703–9.
Article
CAS
Google Scholar
Coimbra FJ, de Jesus VH, Ribeiro HS, Diniz AL, de Godoy AL, de Farias IC, et al. Impact of ypT, ypN, and adjuvant therapy on survival in gastric cancer patients treated with perioperative chemotherapy and radical surgery. Ann Surg Oncol. 2019;26(11):3618–26.
Article
Google Scholar
Pentheroudakis G, Guidelines EMSO, Committee. Recent eUpdates to the ESMO clinical practice guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancer. Ann Oncol. 2019;30(8):1395–7.
Article
CAS
Google Scholar
Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond). 2021;41(8):747–95.
Article
Google Scholar
Mokdad AA, Yopp AC, Polanco PM, Mansour JC, Reznik SI, Heitjan DF, et al. Adjuvant chemotherapy vs postoperative observation following preoperative chemoradiotherapy and resection in gastroesophageal cancer a propensity score-matched analysis. JAMA Oncol. 2018;4(1):31–8.
Article
Google Scholar
Sisic L, Blan S, Nienhüser H, Haag GM, Jäger D, Bruckner T, et al. The postoperative part of perioperative chemotherapy fails to provide a survival benefit in completely resected esophagogastric adenocarcinoma. Surg Oncol. 2020;33:177–88.
Article
Google Scholar
Drake JA, Stiles ZE, Tsao MW, Deneve JL, Glazer ES, Yakoub D, et al. Analysis of the survival impact of postoperative chemotherapy after preoperative chemotherapy and resection for gastric cancer. Ann Surg Oncol. 2021;28(3):1417–27.
Article
Google Scholar
Stijns RC, de Graaf EJ, Punt CJ, Nagtegaal ID, Nuyttens JJ, van Meerten E, et al. Long-term oncological and functional outcomes of chemoradiotherapy followed by organ-sparing transanal endoscopic microsurgery for distal rectal cancer. JAMA Surg. 2019;154(1):47–54.
Article
Google Scholar
Moorcraft SY, Smyth EC, Cunningham D. Adjuvant or neoadjuvant therapy for operable esophagogastric cancer? Gastric Cancer. 2015;18(1):1–10.
Article
CAS
Google Scholar
Haruhiko C, Junichi N, Yoshihide A, Hiroshi Y, Masahiro S, Naoki T, et al. Long-term survival outcomes of advanced gastric cancer patients who achieved a pathological complete response with neoadjuvant chemotherapy: a systematic review of the literature. Ann Surg Oncol. 2015;22(3):787–92.
Article
Google Scholar
Wang XZ, Zeng ZY, Ye X, Sun J, Zhang ZM, Kang WM. Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines. World J Gastrointest Oncol. 2020;12(1):37–53.
Article
CAS
Google Scholar
Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(5):38–49.
Article
Google Scholar
Westerhoff M, Osecky M, Langer R. Varying practices in tumor regression grading of gastrointestinal carcinomas after neoadjuvant therapy: results of an international survey. Mod Pathol. 2020;33(4):676–89.
Article
Google Scholar
Harada K, Kaya DM, Shimodaira Y, Ajan JA. Global chemotherapy development for gastric cancer. Gastric Cancer. 2017;20(1):92–101.
Article
CAS
Google Scholar
Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57.
Article
Google Scholar
Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39(26):2903–13.
Article
CAS
Google Scholar
Zhang XT, Liang H, Li ZY, Xue YW, Wang YN, Zhou ZW, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22(8):1081–92.
Article
CAS
Google Scholar
Yu JR, Gao Y, Chen L, Wu D, Shen QY, Zhao ZC, et al. Effect of S-1 plus oxaliplatin compared with fluorouracil, leucovorin plus oxaliplatin as perioperative chemotherapy for locally advanced, resectable gastric cancer: a randomized clinical trial. JAMA Netw Open. 2022;5(2):e220426.
Article
Google Scholar
Luc G, Gersen-Cherdieu H, Degrandi O, Terrebonne E, Chiche L, Collet D. Impact of postoperative chemotherapy in patients with locally advanced gastroesophageal adenocarcinoma treated with perioperative chemotherapy strategy. Am J Surg. 2015;210(1):15–23.
Article
Google Scholar
Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264–79.
Article
Google Scholar
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): gastriccancer (version1.2019). Available at: www.nccn.org/professionals/physician_gls/PDF/gastric.pdf. Accessed Mar 2022.
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1–21.
Article
Google Scholar
Zhong Q, Chen QY, Parisi A, Ma YB, Lin GT, Desiderio J, et al. Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: a multi-institutional study. Oncologist. 2021;26(1):99–110.
Article
Google Scholar
Zhang Z, Yan J, Hu W, Zhang J, Huo B. Adjuvant chemotherapy provided survival benefit for stage T2N0 gastric cancer with high-risk factors. Neoplasma. 2018;65(4):592–8.
Article
Google Scholar
Haejin I, Kantor O, Sharpe SM, Baker MS, Talamonti MS, Posner MC, et al. Adjuvant therapy improves survival for T2N0 gastric cancer patients with sub-optimal lymphadenectomy. Ann Surg Oncol. 2016;23(6):1956–62.
Article
Google Scholar
Yang K, Chen MX, Choi YY, Zhou ZG, Hyung WJ, Noh SH, et al. The effectiveness of postoperative chemotherapy on pT1bN0 and pT2N0 gastric cancer patients with risk factors: an international dual-center analysis. Yonsei Med J. 2021;62(2):109–17.
Article
CAS
Google Scholar